Immunosuppresants/rituximab: Epstein-Barr virus infection and lack of efficacy: case report.

However, she developed Epstein-Barr virus infection associated with rituximab and unspecified immunosuppresants [ I duration of treatment to reaction onset not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 3.3-years-old girl developed Epstein-Barr virus infection and exhibited lack of efficacy during immunosuppressive therapy with rituximab and unspecified immunosuppresants [ I dosages and routes not stated i ]. [Extracted from the article]